Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup - Trial NCT06153849
Access comprehensive clinical trial information for NCT06153849 through Pure Global AI's free database. This phase not specified trial is sponsored by Changhai Hospital and is currently Not yet recruiting. The study focuses on Bladder Cancer. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Changhai Hospital
Timeline & Enrollment
N/A
Dec 01, 2023
May 01, 2025
Primary Outcome
Correlation between urinary microbiome and BCG instillation efficacy.
Summary
Bacillus Calmette-Guerin (BCG) has been extensively utilized in intravesical instillation
 therapy for patients with medium to high risk non-muscle invasive bladder cancer (NMIBC)
 following transurethral resection of bladder tumor (TURBT). Nevertheless, the efficacy of BCG
 instillation can fluctuate between patients, with 40.5% experiencing disease recurrence
 during BCG therapy. The effectiveness of BCG instillation may be linked to the urinary
 microbiome and immune microenvironment. Additionally, small residual lesions post-TURBT could
 also result in bladder cancer recurrence. Low coverage whole genome sequencing (LC-WGS) can
 be used to detect the urinary microbiome and chromosomal instability (CIN), making it
 feasible to predict the recurrence or progression of bladder cancer during BCG instillation
 therapy. Here, we intend to evaluate the feasibility of detecting urine samples of bladder
 cancer patients receiving BCG instillation to predict the bladder cancer recurrence.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06153849
Non-Device Trial